Successful treatment of subcutaneously disseminated aspergillosis with caspofungin acetate in an allogeneic peripheral blood stem cell transplantation patient

We present a patient with acute myeloid leukaemia who developed subcutaneously disseminated aspergillosis after allogeneic peripheral stem cell transplantation (PSCT). Disseminated aspergillosis after stem cell transplantation has a high mortality despite treatment with amphotericin B or one of the azoles. Aspergillosis in our patient was refractory to amphotericin B and itraconazole but was successfully treated with caspofungin acetate.

Introduction

Disseminated aspergillosis refers to an opportunistic infection by Aspergillus species involving more than one non-contiguous site. In 60% of cases disseminated aspergillosis follows invasive pulmonary aspergillosis. The incidence of pulmonary invasive aspergillosis after allogeneic PSCT has been reported as 4-10%. After transplantation, mortality from disseminated aspergillosis remains high (88.1%-90%) despite treatment with amphotericin B and/or itraconazole. Cutaneous aspergillosis occurs primary at sites of skin injury or secondary to disseminated aspergillosis. Subcutaneous disseminated aspergillosis in an immunocompromised patient was only recently described. This patient was treated with amphotericin B but finally died. Here, we present the second patient with disseminated subcutaneous aspergillosis. Her disease was refractory to amphotericin B and itraconazole but was successfully treated with caspofungin acetate.

Case report

A 53-year-old woman was diagnosed with acute myeloid leukaemia (FAB classification M1) in September 1999. After two courses of induction chemotherapy she received an allogeneic PSCT from an HLA identical sibling after total body irradiation and cyclophosphamide. At the end of the pancytopenic period she developed severe desquamative mucositis leading to respiratory failure which required two days of mechanical ventilation. No infections were found. After three weeks she developed graft-versus-host-disease (GVHD) grade 3 for which treatment with high dose prednisone was started. CMV reactivation was treated by ganciclovir. She recovered and was discharged six weeks after transplantation with GVHD grade 1.

Fourteen weeks after transplantation she reported five painful subcutaneous nodules and severe fatigue and was admitted to the hospital. Medication consisted of prednisone 40 mg daily, mycophenolate mofetil, ganciclovir, fluconazole and co-trimoxazole. Physical examination showed GVHD grade 1 of the skin, subcutaneous nodules on her back, belly and thighs without ulceration of the overlying skin. Body temperature was 36.2°C. Laboratory tests revealed: haemoglobin 9.8 g/dl, WBC 7.0 x 10^9/L with normal differential count, platelets 6 x 10^9/L, alkaline phosphatase 105 U/l, gamma GT 346 U/l and bilirubin 228 µmol/L. Five weeks after starting caspofungin acetate the subcutaneous nodules had almost disappeared and she was discharged. Caspofungin treatment was continued during five months at a dose of 50 mg three times a week. Twelve months after discontinuation of caspofungin acetate she is in complete remission and in good condition. One of three remaining little nodules was surgically excised and showed no evidence of Aspergillus fumigatus.

Discussion

A review spanning 1995 through 1999 reports overall mortality from aspergillosis of 58% and after bone marrow transplantation of 86.7%. For years the treatment of choice has been amphotericin B. Because of intolerable side effects (nephrotoxicity, infusion-related fever and chills), second line drugs like lipid formulations of amphotericin B, itraconazole and voriconazole have been introduced. A trend towards lower mortality after use of lipid amphotericin B and itraconazole was reported, but no randomised studies have confirmed this. Recently, lower mortality after treatment of invasive aspergillosis with voriconazole was demonstrated in a randomised study. New therapeutic options have been investigated due to intolerability of amphotericin B, the price of the lipid formulation and the increasing (acquired or intrinsic) resistance for azoles. The (1,3)-β-D-glucan test is used to support early diagnosis of invasive aspergillosis in clinical trials but no cavitation. Echocardiography was normal. Amphotericin B 1 mg/kg was started and prednisone tapered. After two weeks itraconazole 200 mg p.o. twice daily was added because new lesions appeared. These lesions were progressive and treatment was switched to voriconazole (loading dose 6 mg/kg, daily dose 4 mg/kg i.v.). Her clinical situation deteriorated due to sepsis with E.Coli and to progressive GVHD of the skin and liver. After successful treatment with antibiotics and mycophenolate mofetil, she developed pancytopenia. Recurrence of acute leukaemia was ruled out by marrow examination. Short-tandem-repeat analysis revealed 100% donor cells. Persistent pancytopenia due to medication was suspected. After discontinuation of co-trimoxazole without improvement of blood counts, voriconazole was discontinued despite a slight positive effect on the subcutaneous nodules. Caspofungin acetate was started (loading dose 70 mg, daily dose 50 mg i.v.) after which she slowly recovered. The dose was adjusted to 50 mg every other day because of deteriorating liver function without other signs of progressive GVHD (highest bilirubin 228 µmol/L). Five weeks after starting caspofungin acetate the subcutaneous nodules had almost disappeared and she was discharged.

Figure 1. Subcutaneous localisation of hyphae

Haematologica 2007; 88(3):e36-e37
D-glucan synthase inhibitors, now designated echinocandins, disrupt cell wall glucan formation through non-competitive inhibition of the enzyme complex (1,3)\-(1,6)-D-glucan synthase. This mechanism of action is different from that of amphotericin B and azoles. (1,3)\-(1,6)-D-glucan synthase is absent from mammalian cells. The spectrum of activity of echinocandins includes Aspergillus and Candida species. Caspofungin acetate was found to be superior to amphotericin B in treating candidal esophagitis (response rates 89% vs. 63%). Furthermore, 56 immunocompromised patients with sino-pulmonary or disseminated aspergillosis who were refractory (82%) or intolerant (18%) to amphotericin B, its lipid formulations or azoles were treated with caspofungin acetate and a favourable response was reported in 41% of cases. For disseminated aspergillosis the response rate was 20%. Caspofungin acetate was generally well tolerated. Adverse effects included elevation of serum transaminases (in 10.8%), decreased serum potassium (10.8%) and increased creatinin levels (1.5%). The drug is cleared by the liver necessitating dosage adjustments for patients with hepatic insufficiency. No pharmacokinetic interaction with amphotericin B, itraconazole or mycophenolate was observed. Recently, successful combination therapy of caspofungin acetate and itraconazole in two patients with invasive aspergillosis was reported. Cyclosporine A elevates caspofungin acetate levels and their concomitant use is not recommended. We describe the second patient with proven disseminated subcutaneous aspergillosis. The first patient died, but our patient, who’s disease was refractory to amphotericin B and itraconazole, was successfully treated with caspofungin acetate and 20 months after transplantation she has no signs of Aspergillus infection. Caspofungin acetate seems to be a promising drug for patients with disseminated aspergillosis.


Correspondence: M.E.D. Chamuleau, MD,
Department of Haematology VU University Medical Centre De Boelelaan 1117 1081 HV Amsterdam The Netherlands.
Telephone: +31-204442604 Fax: +31-204442601

References